Triumeq is a fixed-dose combination preparation used for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection.

Administration of Triumeq

Adult Dosage

The recommended dose is one tablet once daily (containing 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine).

Triumeq can be taken with food or on an empty stomach, as food does not affect its efficacy.

Pediatric Dosage

Body weight 6 kg to < 25 kg: Use Triumeq PD oral suspension tablets, administered once daily. The dosage ranges from 3 to 6 tablets per dose, with the exact number determined by the child’s body weight.

Body weight ≥ 25 kg: Use Triumeq regular tablets, one tablet once daily.

Precautions for Administration

Triumeq PD tablets must be fully dispersed in drinking water before oral administration. They should not be swallowed whole, chewed, or crushed.

Use the provided measuring cup or an appropriately sized syringe for administration to ensure accurate dosing.

If a dose is missed, take the missed dose as soon as possible. However, do not take a double dose at the same time to make up for the missed one.

Dose Adjustment of Triumeq

Concomitant Use with Efavirenz, Fosamprenavir/Ritonavir, Tipranavir/Ritonavir, Carbamazepine, or Rifampicin

Adults and pediatric patients with body weight ≥ 25 kg: While taking Triumeq, an additional 50 mg dolutegravir tablet must be administered, with a 12-hour interval between the two doses.

Pediatric patients with body weight 6 kg to < 25 kg: An appropriate dose of dolutegravir oral suspension should be administered 12 hours after taking Triumeq PD.

Concomitant Use with Nevirapine, Oxcarbazepine, Phenytoin, Phenobarbital, or St. John’s Wort

Concomitant use with Triumeq is avoided, as sufficient data on dose adjustment is currently lacking.

Administration Interval with Drugs Containing Polyvalent Cations

Antacids or laxatives containing aluminum/magnesium: These should be taken either 2 hours before or 6 hours after taking Triumeq.

Oral calcium or iron supplements:

If taken with food, they can be administered simultaneously with Triumeq.

If taken on an empty stomach, an interval of at least 2 hours is required between administration of these supplements and Triumeq.

Administration in Special Populations

Patients with Hepatic Impairment

Mild hepatic impairment (Child-Pugh Class A): If dose adjustment of abacavir is needed, single-agent formulations should be used instead of Triumeq.

Moderate to severe hepatic impairment (Child-Pugh Class B or C): Triumeq is contraindicated.

Pregnant Women

Available data indicate that the use of dolutegravir during pregnancy does not significantly increase the risk of neural tube defects.

It is recommended to enroll in an antiretroviral pregnancy registry during treatment to enable continuous monitoring of maternal and infant outcomes.

Lactating Women

Triumeq and its components are excreted in human milk. Breastfeeding during treatment may pose risks such as HIV transmission, development of drug resistance, and adverse reactions in infants. Therefore, breastfeeding is generally not recommended.

Pediatric Patients

Triumeq is indicated for children aged 3 months and older with a body weight of ≥ 6 kg.

The dosage form and dose must be strictly selected based on the child’s body weight, and different dosage forms cannot be used interchangeably.